Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MKenneth S. Thress, Geoffrey R. Oxnard, Zhongwu Lai et al.|Nature Medicine|2015Cited by 1.5k
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung CancerGeoffrey R. Oxnard, Pasi A. Jänne, Kenneth S. Thress et al.|Journal of Clinical Oncology|2016Cited by 843
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V. Sequist, Geoffrey R. Oxnard, Ji‐Youn Han et al.|The Lancet Oncology|2020Cited by 413